133 related articles for article (PubMed ID: 6228283)
1. Prostatic cancer: treatment with long-acting LHRH analogue.
Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
[TBL] [Abstract][Full Text] [Related]
2. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
[TBL] [Abstract][Full Text] [Related]
3. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
Kerle D; Williams G; Ware H; Bloom SR
Br Med J (Clin Res Ed); 1984 Aug; 289(6443):468-9. PubMed ID: 6235888
[No Abstract] [Full Text] [Related]
4. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma.
Walker KJ; Nicholson RI; Turkes AO; Turkes A; Griffiths K; Robinson M; Crispin Z; Dris S
Lancet; 1983 Aug; 2(8347):413-5. PubMed ID: 6135908
[TBL] [Abstract][Full Text] [Related]
5. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms.
Ahmed SR; Brooman PJ; Shalet SM; Howell A; Blacklock NJ; Rickards D
Lancet; 1983 Aug; 2(8347):415-9. PubMed ID: 6135909
[TBL] [Abstract][Full Text] [Related]
7. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
8. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
[No Abstract] [Full Text] [Related]
9. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
[TBL] [Abstract][Full Text] [Related]
11. Endocrine and clinical effects of leuprolide in prostatic cancer.
Vance MA; Smith JA
Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
[TBL] [Abstract][Full Text] [Related]
12. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
[No Abstract] [Full Text] [Related]
13. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
Mahler C; Verhelst J; Chaban M; Denis L
Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer.
Nicholson RI; Walker KJ; Turkes A; Turkes AO; Dyas J; Blamey RW; Campbell FC; Robinson MR; Griffiths K
J Steroid Biochem; 1984 Jan; 20(1):129-35. PubMed ID: 6231416
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
Chodak GW
Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
[TBL] [Abstract][Full Text] [Related]
16. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
17. Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.
Rolandi E; Franceschini R; Giberti C; Brancadoro T; Martorana G; Barreca T
Horm Res; 1988; 30(1):22-5. PubMed ID: 2975631
[TBL] [Abstract][Full Text] [Related]
18. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R
Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893
[TBL] [Abstract][Full Text] [Related]
19. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic resistance to luteinizing hormone-releasing hormone analogue in a patient with prostatic carcinoma.
Jorion JL
J Urol; 1992 Nov; 148(5):1539-40. PubMed ID: 1279215
[No Abstract] [Full Text] [Related]
[Next] [New Search]
